Medtronic (MDT) Offering Possible 18.2% Return Over the Next 22 Calendar Days

This post was originally published on this site

Medtronic’s most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $128.00 short put and a strike $123.00 long put offers a potential 18.2% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $128.00 by expiration. The full premium credit of $0.77 would be kept by the premium seller. The risk of $4.23 would be incurred if the stock dropped below the $123.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.

The RSI indicator is above 80 which suggests that the stock is in overbought territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Medtronic

Medtronic Receives FDA Breakthrough Designation for the Emprint™ Ablation Catheter Kit
Tue, 27 Apr 2021 14:00:00 +0000
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the Emprint™ ablation catheter kit – an investigational device not yet approved or cleared in the United States. The catheter is intended to be used in conjunction with the Emprint™ microwave generator and Medtronic lung navigation platform to provide a minimally invasive, localized treatment of malignant lesions in the lung, and it can be used together with standard of care therapy when indicated.

Medtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence
Tue, 27 Apr 2021 12:00:00 +0000
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational device exemption (IDE) trial to evaluate its internally developed implantable tibial neuromodulation (TNM) device — a therapy designed to provide relief from symptoms of bladder incontinence. The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable TNM device in subjects with bladder incontinence.

Medtronic Partners with Surgical Theater to Provide First Augmented Reality Platform for Use in Real-Time During Complex Cranial Procedures
Mon, 26 Apr 2021 12:00:00 +0000
Medtronic plc (NYSE:MDT), the global leader in medical technology, and Surgical Theater today announced a partnership to interface Surgical Theater’s SyncAR™ augmented reality (AR) technology with Medtronic’s StealthStation™ S8 surgical navigation system. This collaboration will enable neurosurgeons to use AR technology in real-time to enhance visualization during complex cranial procedures. Using fighter-jet simulation technology, the SyncAR platform allows surgeons to visualize structures in the brain, test virtual surgical tools and plan surgeries before entering the operating room. By integrating this technology with the StealthStation S8 cranial solution, surgeons can expand the benefits of AR and, for the first time, see a 360° AR rendering overlaid onto the live surgical site during brain surgeries.

The Zacks Analyst Blog Highlights: Netflix, Medtronic, Stryker, Sysco and EOG Resources
Fri, 23 Apr 2021 13:04:01 +0000
The Zacks Analyst Blog Highlights: Netflix, Medtronic, Stryker, Sysco and EOG Resources

Top Stock Reports for Netflix, Medtronic & Stryker
Thu, 22 Apr 2021 20:31:08 +0000
Top Stock Reports for Netflix, Medtronic & Stryker

Be Sociable, Share!

Related Posts